Podcast

Pharmacy Focus: Oncology Edition - What You Missed at ASCO 2022

This month, we reviewed key topics and interviews from the American Society of Clinical Oncology 2022 Annual Meeting.

This month, we reviewed key topics and interviews from the American Society of Clinical Oncology 2022 Annual Meeting. Experts discussed pharmacists' roles in clinical trial enrollment, CAR T therapies for multiple myeloma, new data from the ATHENA-MONO trial in ovarian cancer, and more.

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Subscribe Now!
Related Videos
Austin Texas | Image credit: Kevin Ruck - stock.adobe.com
Related Content
HRT Hormone Therapy sign surrounded by plants and hormone therapy pills | Image Credit: © tilialucida - stock.adobe.com
July 2nd 2025

Study Links Specific Hormone Therapies to Breast Cancer Risk in Younger Women

Alexandra Gerlach, Associate Editor
An Overview of Intravenous Iron in Heart Failure and the FAIR-HF2 Trial
July 1st 2025

An Overview of Intravenous Iron in Heart Failure and the FAIR-HF2 Trial

Craig Beavers, PharmD, FACC, FAHA, FCCP, BCCP, BCPSAQ Cardiology, CACP Aislinn Antrim, Managing Editor
Microscopic view of bone marrow slide feature are suggestive Multiple myeloma, also known as myeloma, is a type of bone marrow cancer.
Published: July 2nd 2025 | Updated: July 2nd 2025

FDA Approves Linvoseltamab-Gcpt for Treatment of Relapsed or Refractory Multiple Myeloma

Luke Halpern, Assistant Editor
Pharmacy Times, Pharmacy Focus Oncology Edition
June 27th 2025

Allen's Story: The Promising Potential of Intratumoral Immunotherapy

Alexandra Gerlach, Associate Editor
Group of women holding breast cancer ribbon | Image Credit: © Rawpixel.com - stock.adobe.com
July 1st 2025

Study Reveals Alarming Gaps in HER2 Therapy Access for Patients With Breast Cancer

Alexandra Gerlach, Associate Editor
digital representation of car t cells targeting lymphoma cells vibrant and scientific lymphoma car t cell therapy for lymphoma
June 30th 2025

FDA Removes REMS for Currently Approved BCMA-, CD19-Directed CAR T Cell Immunotherapies

Luke Halpern, Assistant Editor